©2025 Stanford Medicine
Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
Trial ID: NCT00002756
Purpose
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and giving them as induction intensification may kill more cancer cells.
PURPOSE: This phase II trial is studying how well induction intensification works in treating infants with newly diagnosed acute lymphocytic leukemia.
Official Title
Induction Intensification in Infant ALL: A Children's Oncology Group Study
Stanford Investigator(s)
Eligibility
DISEASE CHARACTERISTICS:
* Newly diagnosed acute lymphoblastic leukemia (ALL) or acute undifferentiated leukemia
* No infants less than 36 weeks' gestation
* CNS or testicular disease permitted
* No B-cell ALL or acute myeloid leukemia
* Previously untreated except for the following:
* Steroid treatment within 48 hours of diagnosis allowed with physical examination and differential CBC immediately prior to beginning steroids
* Concurrent registration on protocol POG-9900 (ALL classification study) required
* Patients registered on POG-9407 are eligible for the pharmacokinetic part of the study
PATIENT CHARACTERISTICS:
Age:
* Under 1 at diagnosis
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Not specified
Other:
* No uncontrolled infection
* Adequate major organ function
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* Not specified
Endocrine therapy:
* See Disease Characteristics
* No concurrent chronic steroid treatment
Radiotherapy:
* Not specified
Surgery:
* Not specified
Other:
* No other concurrent anticancer therapy
Intervention(s):
biological: filgrastim
drug: asparaginase
drug: cyclophosphamide
drug: cytarabine
drug: daunorubicin hydrochloride
drug: etoposide
drug: leucovorin calcium
drug: mercaptopurine
drug: methotrexate
drug: prednisone
drug: therapeutic hydrocortisone
drug: vincristine sulfate
biological: filgrastim
drug: asparaginase
drug: cyclophosphamide
drug: cytarabine
drug: daunorubicin hydrochloride
drug: etoposide
drug: leucovorin calcium
drug: mercaptopurine
drug: methotrexate
drug: prednisone
drug: therapeutic hydrocortisone
drug: vincristine sulfate
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305